A Follow-Up Shiftability Study of Arbaclofen with an Open-Label Extension for the study of Biomarkers for Treatment for Social Function in Children and Adolescents with Autism Spectrum Disorders

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508407-20-00

Acronym

AIMS-2-CT2

Enrollment

105

Registered

2024-09-23

Start date

2025-11-20

Completion date

Unknown

Last updated

2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autism spectrum disorder

Brief summary

Change in power in the low frequency bands (theta/alpha) (between visits 1 and 2).

Detailed description

Latency of N170 change (between visits 1 and 2)

Interventions

DRUGARBACLOFEN 10mg

DRUGARBACLOFEN 5mg

DRUGARBACLOFEN 15mg

DRUGARBACLOFEN 20mg

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change in power in the low frequency bands (theta/alpha) (between visits 1 and 2).	—

Secondary

Measure	Time frame
Latency of N170 change (between visits 1 and 2)	—

Countries

France, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026